A press release from IDT on May 4, 2007 revealed an agreement signed by both parties indicating an alliance to combine efforts. The goal is to offer oligo-synthesis encompassing the full spectrum of drug develoment. IDT and Agilent feel this merger will target their customer base who are moving from research phase to clinical phase, and can help to spare some of the costs and time involved in that transition.
The agreement forms a development pathway for customers:
-screening and small-scale products at IDT facility
-mid-scale (such as products for animal studies) produced at IDT's Belgium facility
-large-scale production at Agilent's Nucleic Acid Solutions Division for use of Active Pharmaceutical Ingredients (API) for use in clincal-trial and marketed drug production. Agilent's oligos comply with pharmaceutical GMP guidelines.
For the full press release, see this link: